Zentiva consolidates its position on the analgesic market

The company owns Algocalmin and Antinevralgic brands after taking over the Sicomed drug producer three years ago. Zentiva launched Ibalgin in 2006, a product similar to Algocalmin, and now announced the launch of Ibalgin Forte.

“Analyzing the trends in 2006 and 2007, the analgesic and anti-inflammatory OTC market has dropped in terms of volume, but increased in value. Patients have begun to opt for treatment quality and we estimate that this trend will continue in 2008,” said Iolanda Bilaus, Zentiva Brand Manager.

Ibalgin is the best-sold product on the other markets where Zentiva is operating. The company claims 54 percent of the local market in terms of sales and 47 percent in terms of value. Its main competitor is British company Reckitt Benckiser, producer of Nurofen.